Compare GAIA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | GANX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 78.2M |
| IPO Year | 1999 | 2021 |
| Metric | GAIA | GANX |
|---|---|---|
| Price | $2.41 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $7.50 |
| AVG Volume (30 Days) | 72.2K | ★ 495.6K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,500,000.00 | $55,180.00 |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $2.30 | $1.41 |
| 52 Week High | $6.39 | $4.34 |
| Indicator | GAIA | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 43.30 |
| Support Level | $2.37 | $1.60 |
| Resistance Level | $3.41 | $2.09 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.73 | 47.62 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.